$AORT

Merit Medical (MMSI) reported Q2 revenue growth of 9%, raising full-year guidance and seeing a 4.5% stock increase. ICU Medical (ICUI) reported flat revenue but beat EPS estimates, with a 2.1% stock decline. Penumbra (PEN) saw 14.9% revenue growth but missed EPS estimates, with a flat stock. Artivion (AORT) reported 11.3% revenue growth and beat EPS estimates, but its stock fell 19.2%.

Artivion Inc. (AORT) reported Q2 2026 revenue growth of 11% to $125.8M, driven by its aortic arch portfolio. However, it posted a net loss of $13.5M, reversing from a profit a year earlier. The company completed the Endospan acquisition and received FDA approval for AMDS. Despite growth, profitability declined, and guidance was reiterated without an increase.

GREEN ANDREW M (SVP, Regulatory and Quality) sold 11,480 shares of ARTIVION, INC. (AORT) at $24.97 ($0.29M total) on 2026-09-10.

GREEN ANDREW M (SVP, Regulatory and Quality) sold 8,003 shares of ARTIVION, INC. (AORT) at an average of $27.03 ($26.02–$27.26, $0.22M total) across 2 trades over 2026-09-02 to 2026-09-03.

Mackin James P (President & CEO) sold 70,000 shares of ARTIVION, INC. (AORT) at $28.96 ($2.03M total) on 2026-08-19.

Artivion (AORT) reported Q2 2026 revenue of $125.76M, up from $112.97M a year earlier, but shifted from net income to a loss of $13.51M. H1 2026 revenue rose to $242.09M, but the company moved to a net loss of $12.09M. The company projects $619.8M revenue and $44.7M earnings by 2029, requiring 10.6% yearly revenue growth.

Artivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.

Artivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.

Artivion’s Q2 update highlights 12% YoY growth in stent graft revenues and 18% growth in its On-X mechanical heart valve portfolio. The company says its NEXUS Aortic Arch Stent Graft acquisition (Endospan) completed and that AMDS received full FDA approval, supporting adoption. Management expects near-term margin and cash flow pressure from R&D and integration.

Artivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.